AR097651A1 - Métodos y composiciones que comprenden polipéptidos recombinantes purificados - Google Patents

Métodos y composiciones que comprenden polipéptidos recombinantes purificados

Info

Publication number
AR097651A1
AR097651A1 ARP140103417A ARP140103417A AR097651A1 AR 097651 A1 AR097651 A1 AR 097651A1 AR P140103417 A ARP140103417 A AR P140103417A AR P140103417 A ARP140103417 A AR P140103417A AR 097651 A1 AR097651 A1 AR 097651A1
Authority
AR
Argentina
Prior art keywords
less
plbl2
purified
cdr
seq
Prior art date
Application number
ARP140103417A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR097651A1 publication Critical patent/AR097651A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)

Abstract

Reivindicación 1: Una composición que comprende un anticuerpo monoclonal anti-IL13 purificado de células huésped de ovario de hámster chino, en donde la composición comprende el anticuerpo anti-IL13 y una cantidad residual de hámster PLBL2, en donde la cantidad de PLBL2 de hámster es inferior a 20 ng/mg o inferior a 15 ng/mg o inferior a 10 ng/mg o inferior a 8 ng/mg o inferior a 5 ng/mg o inferior a 3 ng/mg o inferior a 2 ng/mg o inferior a 1 ng/mg o inferior a 0,5 ng/mg. Reivindicación 2: La composición de acuerdo con la reivindicación 1, en donde el anticuerpo anti-IL13 comprende tres CDR de cadena pesada, CDR-H1 que tiene la secuencia de aminoácidos de SEQ ID Nº 1, CDR-H2 que tiene la secuencia de aminoácidos de SEQ ID Nº 2 y CDR-H3 que tiene la secuencia de aminoácidos de SEQ ID Nº 3 y tres CDR de cadena liviana, CDR-L1 que tiene la secuencia de aminoácidos de SEQ ID Nº 4, CDR-L2 que tiene la secuencia de aminoácidos de SEQ ID Nº 5 y CDR-L3 que tiene la secuencia de aminoácidos de SEQ ID Nº 6. Reivindicación 12: Una preparación de anticuerpo monoclonal anti-IL13 purificado aislado de células huésped de ovario de hámster chino, en donde la preparación se purifica por medio de un proceso que comprende una etapa de cromatografía de interacción hidrofóbica (HIC) produciendo así una preparación purificada, en donde la preparación purificada comprende el anticuerpo anti-IL13 y una cantidad residual de hámster PLBL2, en donde la cantidad de PLBL2 de hámster es inferior a 20 ng/mg o inferior a 15 ng/mg o inferior a 10 ng/mg o inferior a 8 ng/mg o inferior a 5 ng/mg o inferior a 3 ng/mg o inferior a 2 ng/mg o inferior a 1 ng/mg o inferior a 0,5 ng/mg. Reivindicación 35: Un método de purificación de un polipéptido recombinante producido en células huésped de ovario de hámster chino, en donde el método proporciona una preparación purificada que comprende el polipéptido recombinante y una cantidad residual de hámster PLBL2. Reivindicación 72: Una composición que comprende un anticuerpo monoclonal anti-Ab purificado de células huésped de ovario de hámster chino, en donde la composición comprende el anticuerpo anti-Ab y una cantidad residual de hámster PLBL2, en donde la cantidad de PLBL2 de hámster es inferior a 20 ng/mg o inferior a 15 ng/mg o inferior a 10 ng/mg o inferior a 8 ng/mg o inferior a 5 ng/mg o inferior a 3 ng/mg o inferior a 2 ng/mg o inferior a 1 ng/mg o inferior a 0,5 ng/mg. Reivindicación 94: Un método de tratamiento de un trastorno mediado por IL-13 en un paciente que comprende la administración de una composición de tratamiento al paciente, en donde la composición de tratamiento comprende la composición de acuerdo con cualquiera de las reivindicaciones 1 - 8.
ARP140103417A 2013-09-13 2014-09-12 Métodos y composiciones que comprenden polipéptidos recombinantes purificados AR097651A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361877517P 2013-09-13 2013-09-13

Publications (1)

Publication Number Publication Date
AR097651A1 true AR097651A1 (es) 2016-04-06

Family

ID=52666315

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140103417A AR097651A1 (es) 2013-09-13 2014-09-12 Métodos y composiciones que comprenden polipéptidos recombinantes purificados
ARP200100914A AR118560A2 (es) 2013-09-13 2020-04-01 Métodos y composiciones que comprenden polipéptidos recombinantes purificados

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP200100914A AR118560A2 (es) 2013-09-13 2020-04-01 Métodos y composiciones que comprenden polipéptidos recombinantes purificados

Country Status (18)

Country Link
US (7) US9920120B2 (es)
EP (3) EP3683232A1 (es)
JP (4) JP6751344B2 (es)
KR (2) KR102373930B1 (es)
CN (1) CN105722532A (es)
AR (2) AR097651A1 (es)
AU (2) AU2014318615B2 (es)
BR (1) BR112016004413A2 (es)
CA (2) CA3184564A1 (es)
HK (1) HK1225988A1 (es)
IL (1) IL244149A0 (es)
MX (3) MX2016003202A (es)
MY (2) MY176026A (es)
NZ (3) NZ756749A (es)
RU (1) RU2671481C2 (es)
SG (2) SG11201601823TA (es)
WO (1) WO2015038888A1 (es)
ZA (4) ZA201601965B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2970378T3 (pl) 2013-03-15 2021-12-06 Biogen Ma Inc. Chromatografia oddziaływań hydrofobowych białek w warunkach bez soli
EP3683232A1 (en) * 2013-09-13 2020-07-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
TW201702380A (zh) 2015-02-27 2017-01-16 再生元醫藥公司 宿主細胞蛋白質修飾
JP7091238B2 (ja) * 2015-08-20 2022-06-27 ジェネンテック， インコーポレイテッド Ｆｋｐａの精製、及び組換えポリペプチドの産生のためのその使用
SI3337817T1 (sl) 2015-08-21 2021-12-31 F. Hoffmann - La Roche Ag Postopek za redukcijo beljakovin gostiteljske celice pri afinitetni kromatografiji
WO2017032686A1 (en) * 2015-08-21 2017-03-02 F. Hoffmann-La Roche Ag Method for the reduction of host cell proteins in affinity chromatography
AU2017251360A1 (en) * 2016-04-14 2018-11-01 Lonza Ltd Compositions and methods for the detection of host cell proteins
US10688412B2 (en) * 2016-07-25 2020-06-23 Cehpalon, Inc. Affinity chromatography wash buffer
MY196321A (en) 2016-08-16 2023-03-24 Regeneron Pharma Methods for Quantitating Individual Antibodies From a Mixture
KR102489451B1 (ko) 2016-09-07 2023-01-16 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 항체를 정제하는 방법
US11254753B2 (en) * 2016-10-06 2022-02-22 Glaxosmithkline Intellectual Property Development Limited Antibodies with reduced binding to process impurities
WO2018081203A1 (en) 2016-10-25 2018-05-03 Regeneron Pharmaceuticals, Inc. Methods and systems for chromatography data analysis
MX2019007564A (es) 2016-12-23 2019-09-06 Serum Institute Of India Pvt Ltd Metodos mejorados para estimular la productividad de anticuerpos en el cultivo de celulas de mamiferos y reducir la agregacion durante los procesos de formulacion corriente abajo y formulaciones de anticuerpos estables obtenidas a partir de los mismos.
TW202003555A (zh) * 2018-03-07 2020-01-16 英商葛蘭素史克智慧財產發展有限公司 用於純化重組多肽之方法
TW202005694A (zh) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
US20220267369A1 (en) * 2018-07-25 2022-08-25 Merck Sharp & Dohme Corp. Methods of separating host cell lipases from a production protein in chromatographic processes
SG11202107192VA (en) 2019-01-23 2021-07-29 Daiichi Sankyo Co Ltd Methods for purifying antibodies comprising of a process by using activated carbon materials
WO2020157749A1 (en) * 2019-01-29 2020-08-06 Bnai Zion Medical Center Anti il-17 antibody for use in treating chronic spontaneous urticaria
CA3156649A1 (en) * 2019-10-04 2021-04-08 Merck Patent Gmbh PROTEIN PURIFICATION AND VIRAL INACTIVATION
AU2021213153A1 (en) * 2020-01-29 2022-08-04 Merck Sharp & Dohme Llc Methods of separating host cell lipases from an anti-LAG3 antibody production
CA3216037A1 (en) * 2021-05-03 2022-11-10 Agilent Technologies, Inc. Chimeric immunogens and methods for making polyclonal antibodies against specific epitopes
US20240199688A1 (en) * 2022-05-02 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity
CN117169518B (zh) * 2023-11-03 2024-01-19 赛德特(北京)生物工程有限公司 T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3645090A (en) 1969-06-19 1972-02-29 Citizen Watch Co Ltd Day-date quick-adjuster for calender timepiece
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3422247A1 (de) 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Gluco-oligosaccharid-gemisch und verfahren zu seiner herstellung
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US4847745A (en) 1988-11-16 1989-07-11 Sundstrand Corp. Three phase inverter power supply with balancing transformer
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5011778A (en) 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2071908C (en) 1989-12-20 2002-04-30 Lata Ramanathan Antibody antagonists of human interleukin-4
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ES2054601T3 (es) 1991-03-29 1996-04-01 Sanofi Sa Proteina con actividad de tipo citoquina, adn recombinante codante para esta proteina, celulas y microorganismos transformados.
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5965709A (en) 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
US5994514A (en) 1991-08-14 1999-11-30 Genentech, Inc. Immunoglobulin variants
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
AU3658093A (en) 1992-02-10 1993-09-03 Seragen, Inc. Desensitization to specific allergens
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2096289A1 (en) 1992-05-15 1993-11-16 Wouter Musters Cloning and expression of dna encoding a ripening form of a polypeptide having rhamnogalacturonase activity
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
AU5010793A (en) 1992-08-21 1994-03-15 Schering Corporation Human interleukin-13
US5596072A (en) 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
DE69415669T2 (de) 1993-05-17 1999-07-01 Genentech Inc Sialidase defiziente zellen
EP0721346B1 (en) 1993-09-02 1998-06-10 Trustees of Dartmouth College Methods for inducing antigen-specific t cell tolerance
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US6518061B1 (en) 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6911530B1 (en) 1995-10-23 2005-06-28 Amrad Operations, Pty., Ltd. Haemopoietin receptor and genetic sequences encoding same
AU718899C (en) 1995-10-23 2004-01-29 Amrad Operations Pty. Limited A novel haemopoietin receptor and genetic sequences encoding same
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US7078494B1 (en) 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
AU6450196A (en) 1996-06-12 1998-01-07 Human Genome Sciences, Inc. Hr-1 receptor
WO1998010638A1 (en) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
IL130061A (en) 1996-11-27 2001-09-13 Genentech Inc Affinity purification of polypeptide on protein a matrix
US6743604B1 (en) 1996-12-13 2004-06-01 Smithkline Beecham Corporation Substances and their uses
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
TR199902191T2 (xx) 1997-01-10 1999-12-21 Biogen, Inc. Anti-CD40L bile�ikleri ile lupus nefritis tedavisi
BR9806793A (pt) 1997-01-22 2000-05-16 Univ Texas Processos e composições de fator tissular para coagulação e tratamento de tumores.
US6576232B1 (en) 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
US6482403B1 (en) 1998-05-29 2002-11-19 Heska Corporation Caniney IL-13 immunoregulatory proteins and uses thereof
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
GB9820014D0 (en) 1998-09-14 1998-11-04 Cancer Res Campaign Tech Receptor antagonists and uses thereof
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
DE19848026A1 (de) 1998-10-17 2000-04-20 Bayer Ag Verfahren zur Herstellung von Bis(4-hydroxyaryl)alkanen
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
DK1141286T3 (da) 1998-12-14 2007-02-19 Genetics Inst Llc Kæde af cytokinreceptorer
AU2750800A (en) 1999-02-01 2000-08-18 Amgen Canada Inc. Materials and methods to inhibit hodgkin and reed sternberg cell growth
CA2404763A1 (en) 1999-11-11 2001-05-17 Raj K. Puri Mutated il-13 molecules and their uses
US20100041039A1 (en) 2000-01-15 2010-02-18 Synageva Biopharma Corp. Analysis of nucleic acid obtained from nucleated red blood cells
BRPI0108676B8 (pt) 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
CN100455599C (zh) 2000-03-03 2009-01-28 协和发酵工业株式会社 基因重组抗体及其抗体片段
CN1323812A (zh) 2000-05-16 2001-11-28 上海博德基因开发有限公司 一种新的多肽——人白细胞介素－13(il－13)受体11和编码这种多肽的多核苷酸
WO2002033073A1 (fr) 2000-10-20 2002-04-25 Chugai Seiyaku Kabushiki Kaisha Anticorps agoniste degrade
DK1333850T3 (da) 2000-10-20 2008-12-01 Genetics Inst Anvendelse af IL-13-inhibitorer til behandling af tumorer
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CA2447832C (en) 2000-12-22 2012-09-25 Jamshid Tanha Phage display libraries of human vh fragments
CA2452058A1 (en) 2001-06-26 2003-01-09 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
US20030023555A1 (en) 2001-07-26 2003-01-30 Cashworks, Inc. Method and system for providing financial services
EP1449850B9 (en) 2001-08-31 2011-05-11 Kyowa Hakko Kirin Co., Ltd. Human cdr-grafted antibodies and antibody fragments thereof
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1578912A4 (en) 2001-10-26 2007-12-26 Centocor Inc IL-13 MUTEIN PROTEINS, ANTIBODIES, COMPOSITIONS, METHODS AND USES
ATE419007T1 (de) 2001-11-07 2009-01-15 Cytos Biotechnology Ag Antigenraster welche il-5, il-13 oder eotaxin präsentieren, zur behandlung von allergischen, eosinophilen erkrankungen
ATE417858T1 (de) 2002-02-05 2009-01-15 Genentech Inc Proteinaufreinigung
AU2003223497A1 (en) 2002-04-05 2003-10-27 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
US20040060102A1 (en) 2002-04-10 2004-04-01 Interspiro, Inc. Garments for biological, chemical and fire protection
JP4319979B2 (ja) 2002-04-26 2009-08-26 ジェネンテック・インコーポレーテッド タンパク質の非アフィニティ精製
DE60239566D1 (de) 2002-06-14 2011-05-05 Brigham And Women S Hospital Boston Verfahren zur behandlung und prävention von kolitis, an der il-13 und nk-t zellen beteiligt sind
WO2004019974A2 (en) 2002-08-30 2004-03-11 Glaxo Group Limited Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
AU2003260748A1 (en) 2002-08-30 2004-03-19 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
US7575747B2 (en) 2003-02-10 2009-08-18 Applied Molecular Evolution Aβ binding molecules
US7157276B2 (en) 2003-06-20 2007-01-02 Biogen Idec Inc. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
CA2529819A1 (en) 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
SG10201404273QA (en) 2003-12-23 2014-10-30 Genentech Inc Novel anti-il 13 antibodies and uses thereof
PL2311873T3 (pl) 2004-01-07 2019-01-31 Novartis Vaccines And Diagnostics, Inc. Przeciwciało monoklonalne specyficzne wobec M-CSF i jego zastosowania
WO2005071410A1 (en) 2004-01-13 2005-08-04 Tanox, Inc. Detecting and quantifying host cell proteins in recombinant protein products
US20050226883A1 (en) 2004-02-06 2005-10-13 Paul Averback Humanized antibody
ES2375627T3 (es) 2004-02-23 2012-03-02 Eli Lilly And Company Anticuerpos anti-abeta.
US20070037966A1 (en) * 2004-05-04 2007-02-15 Novo Nordisk A/S Hydrophobic interaction chromatography purification of factor VII polypeptides
DE602005019038D1 (de) 2004-05-04 2010-03-11 Novo Nordisk Healthcare Ag O-verknüpfte glykoformen von faktor vii und verfahren zu deren herstellung
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
AU2005299716B2 (en) 2004-10-22 2012-09-06 Amgen Inc. Methods for refolding of recombinant antibodies
EP1838150B1 (en) 2004-12-24 2013-06-26 Commonwealth Scientific and Industrial Research Organisation Pesticide compositions and methods
RU2457214C2 (ru) 2005-03-11 2012-07-27 Вайет Способ хроматографии в режиме слабого распределения
KR20080006601A (ko) 2005-04-11 2008-01-16 메다렉스, 인코포레이티드 단백질 정제 방법
CN104926938B (zh) 2005-06-17 2019-06-04 惠氏有限责任公司 纯化含Fc区蛋白的方法
JP3982545B2 (ja) 2005-09-22 2007-09-26 ダイキン工業株式会社 空気調和装置
KR101363777B1 (ko) 2005-09-30 2014-02-14 메디뮨 리미티드 인터루킨―１３ 항체 조성물
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
US7667557B2 (en) 2005-12-06 2010-02-23 Tdk Corporation Thin-film bandpass filter using inductor-capacitor resonators
WO2007068429A1 (en) 2005-12-12 2007-06-21 F. Hoffmann-La Roche Ag Antibodies against amyloid beta 4 with glycosylated in the variable region
RU2551782C2 (ru) 2005-12-12 2015-05-27 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
KR20080090484A (ko) 2005-12-30 2008-10-08 메르크 파텐트 게엠베하 ＧＰ130 에 대한, ＩＬ-6Ｒα 와 복합체를 형성한 ＩＬ-6의 결합을 방해하는 항-ＩＬ-6 항체
US7563875B2 (en) 2006-03-20 2009-07-21 The United States of America as represented by the Sercretary of the Army Recombinant chimeric human anti-botulinum antibodies
SG170837A1 (en) * 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
AU2007240624A1 (en) 2006-04-21 2007-11-01 Wyeth Methods for high-throughput screening of cell lines
PL2046833T3 (pl) 2006-07-14 2014-01-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
WO2008036863A2 (en) 2006-09-21 2008-03-27 Verenium Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
EP2074145B1 (en) 2006-10-02 2017-08-16 AC Immune S.A. Humanized antibody against amyloid beta
RS53387B (en) 2006-10-04 2014-10-31 Genentech, Inc. ELISA FOR VEGF
US8383350B1 (en) 2006-12-20 2013-02-26 Merck Sharp & Dohme Corp. Assay for detection of IL-10 antibodies
US20090060906A1 (en) 2007-01-09 2009-03-05 Wyeth Anti-IL-13 antibody formulations and uses thereof
WO2008140455A1 (en) 2007-05-15 2008-11-20 Tanox, Inc. Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies
KR20150055103A (ko) 2007-06-12 2015-05-20 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
KR101600095B1 (ko) 2007-06-12 2016-03-07 에이씨 이뮨 에스.에이. 모노클로널 항 베타 아밀로이드 항체
US9433922B2 (en) 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
NZ601858A (en) 2007-10-05 2014-03-28 Genentech Inc Methods and compositions for diagnosis and treatment of amyloidosis
CA2701790A1 (en) 2007-10-05 2009-04-16 Ac Immune S.A. Use of humanized anti-beta-amyloid antibody in ocular diseases
WO2009058769A1 (en) * 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
NZ588853A (en) 2008-03-31 2013-07-26 Genentech Inc Compositions and methods for treating and diagnosing asthma
WO2009131643A1 (en) 2008-04-21 2009-10-29 Monabio, Inc. Immunoassay for specific determination of s-adenosymethionine and analogs thereof in biological samples
KR20170023209A (ko) 2008-05-05 2017-03-02 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
CN106039307A (zh) 2008-08-05 2016-10-26 东丽株式会社 用于治疗和预防癌症的药物组合物
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
GB0818674D0 (en) 2008-10-10 2008-11-19 Univ Bath Materials and methods for resolving polyhydric species by electrophoresis
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
RU2011120178A (ru) 2008-10-20 2012-11-27 Эбботт Лэборетриз Антитела, которые связываются с il-12, и способы их очистки
JP5808249B2 (ja) 2008-10-20 2015-11-10 アッヴィ・インコーポレイテッド プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製
BRPI0919545A2 (pt) 2008-10-20 2015-12-08 Abbott Lab anticorpos que se ligam a il-18 e métodos de purificar os mesmos
CN101979404B (zh) 2008-12-09 2015-01-14 厦门大学 H5亚型禽流感病毒保守中和表位模拟肽及其用途
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
WO2011010940A1 (en) 2009-07-19 2011-01-27 Serguei Zavtrak Solar electric power generator
KR20190018041A (ko) 2009-08-06 2019-02-20 제넨테크, 인크. 단백질 정제 시의 바이러스 제거의 개선방법
LT3023438T (lt) 2009-09-03 2020-05-11 Merck Sharp & Dohme Corp. Anti-gitr antikūnai
UA109884C2 (uk) 2009-10-16 2015-10-26 Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
AU2010310748C1 (en) * 2009-10-20 2015-11-26 Abbvie Inc. Isolation and purification of anti-IL-13 antibodies using Protein A affinity chromatography
TR201806936T4 (tr) 2010-01-29 2018-06-21 Chugai Pharmaceutical Co Ltd Anti-dll3 antikoru.
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
NZ602161A (en) 2010-03-04 2014-12-24 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
DK3789038T3 (da) 2010-05-14 2022-10-17 Univ Leland Stanford Junior Humaniserede og kimære monoklonale antistoffer mod cd47
SG10201503904XA (en) 2010-05-17 2015-06-29 Livtech Inc Anti-human trop-2 antibody having antitumor activity in vivo
NZ603648A (en) 2010-05-25 2014-12-24 Genentech Inc Methods of purifying polypeptides
US8603478B2 (en) 2010-07-06 2013-12-10 Aveo Pharmaceuticals, Inc. Anti-RON antibodies
JP6081356B2 (ja) 2010-07-30 2017-02-15 エーシー イミューン エス．エー． 安全で機能的なヒト化抗βアミロイド抗体
JP2014501491A (ja) 2010-09-29 2014-01-23 ジェネンテック， インコーポレイテッド 抗体組成物及び使用の方法
TWI689314B (zh) * 2010-11-30 2020-04-01 建南德克公司 低親和力血腦障壁受體抗體及其用途
EP3447491A3 (en) 2010-12-16 2019-06-05 F. Hoffmann-La Roche AG Diagnosis and treatments relating to th2 inhibition
LT2699264T (lt) 2011-04-20 2018-07-10 Medimmune, Llc Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1
LT3091029T (lt) * 2011-10-31 2023-02-27 F. Hoffmann-La Roche Ag Anti-il13 antikūno kompozicijos
US20140288278A1 (en) * 2011-10-31 2014-09-25 Joseph Nti-Gyabaah Chromatography process for resolving heterogeneous antibody aggregates
CN104066748A (zh) * 2011-11-21 2014-09-24 霍夫曼-拉罗奇有限公司 抗c-met抗体的纯化
EP2791176B1 (en) 2011-12-15 2018-07-11 Prestige Biopharma Pte. Ltd. A method of antibody purification
WO2013120497A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
US9732156B2 (en) 2012-02-29 2017-08-15 Gilead Biologics, Inc. Methods of treating rheumatoid arthritis using antibodies to matrix metalloproteinase 9
KR102332302B1 (ko) 2013-09-13 2021-12-01 제넨테크, 인크. 세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법
EP3683232A1 (en) * 2013-09-13 2020-07-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides

Also Published As

Publication number Publication date
AU2014318615A1 (en) 2016-04-21
US20230250165A1 (en) 2023-08-10
MX2016003202A (es) 2016-06-07
AU2014318615B2 (en) 2020-03-12
US11667706B2 (en) 2023-06-06
RU2016108828A3 (es) 2018-05-29
AU2020200502A1 (en) 2020-02-13
JP2016539176A (ja) 2016-12-15
NZ718144A (en) 2022-05-27
ZA202201361B (en) 2023-11-29
US20210115126A1 (en) 2021-04-22
US20160319012A1 (en) 2016-11-03
AR118560A2 (es) 2021-10-20
NZ756750A (en) 2022-05-27
KR102373930B1 (ko) 2022-03-11
NZ756749A (en) 2022-05-27
MY176026A (en) 2020-07-22
EP4331605A3 (en) 2024-05-22
MX2021005364A (es) 2021-06-30
AU2020200502B9 (en) 2022-03-24
HK1225988A1 (zh) 2017-09-22
US20180291094A1 (en) 2018-10-11
US20180273615A1 (en) 2018-09-27
JP2019178139A (ja) 2019-10-17
KR20220034930A (ko) 2022-03-18
CA3184564A1 (en) 2015-03-19
MY193481A (en) 2022-10-17
CA2921999A1 (en) 2015-03-19
ZA202101142B (en) 2022-09-28
ZA201801849B (en) 2021-07-28
SG11201601823TA (en) 2016-04-28
US10597447B2 (en) 2020-03-24
CN105722532A (zh) 2016-06-29
KR20160052724A (ko) 2016-05-12
RU2016108828A (ru) 2017-10-18
SG10201802525QA (en) 2018-04-27
US9920120B2 (en) 2018-03-20
ZA201601965B (en) 2018-11-28
US20180312585A1 (en) 2018-11-01
US10597446B2 (en) 2020-03-24
EP3683232A1 (en) 2020-07-22
AU2014318615A9 (en) 2016-06-16
CA2921999C (en) 2023-03-21
EP4331605A2 (en) 2024-03-06
EP3043820A4 (en) 2017-07-12
AU2020200502B2 (en) 2022-03-10
JP6751344B2 (ja) 2020-09-02
WO2015038888A1 (en) 2015-03-19
EP3043820A1 (en) 2016-07-20
JP2022036971A (ja) 2022-03-08
US10822404B2 (en) 2020-11-03
JP6982027B2 (ja) 2021-12-17
IL244149A0 (en) 2016-04-21
RU2671481C2 (ru) 2018-10-31
US10494429B2 (en) 2019-12-03
BR112016004413A2 (pt) 2017-10-17
JP7489953B2 (ja) 2024-05-24
MX2021005358A (es) 2021-06-30
US20180291095A1 (en) 2018-10-11
KR102571391B1 (ko) 2023-08-29
WO2015038888A9 (en) 2016-03-17
JP2024059617A (ja) 2024-05-01

Similar Documents

Publication Publication Date Title
AR097651A1 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
AR080501A1 (es) Anticuerpos anti factor determinante antigenico de la muerte programada 1 (anti-pd1)
RU2019118359A (ru) Антитело к cd73 человека
PE20121646A1 (es) Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica
PE20231958A1 (es) Moleculas de union a pd-1 y metodos de uso de las mismas
RU2012147286A (ru) Гуманизированные антитела к фактору d и их применения
AR086044A1 (es) Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
PE20212324A1 (es) Anticuerpos que reconocen tau
RU2017125758A (ru) Антитела к с5 и способы их применения
JP2016512551A5 (es)
RU2013143358A (ru) Анти-fgfr4 антитела и способы их применения
PE20190212A1 (es) Anticuerpos anti_ige
AR109533A2 (es) Anticuerpos anti-fractalkina o un fragmento de unión a la fkn de éste, composiciones que lo comprenden y métodos para tratar trastornos inflamatorios
CO6480962A2 (es) Anticuerpos anti-vegf y sus usos
AR088579A1 (es) Formulaciones de anticuerpos
PE20040947A1 (es) MOLECULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA
PE20141547A1 (es) Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile
PE20130580A1 (es) Proteinas terapeuticas de union a dll4
RU2012129735A (ru) Антитела к her3 и их применения
NZ596712A (en) Anti cxcr4 antibodies for the treatment of hiv
AR110659A1 (es) Proteínas de unión a antígenos anti-neuropilin y método para su uso
PE20170687A1 (es) Proteinas de enlace a cd127
AR102594A1 (es) ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO
AR075925A1 (es) Anticuerpos anti-alfa5beta1 (alfa5beta1: glicoproteina integrina) y sus usos
AR105938A1 (es) Anticuerpo anti-epha4